Qu Min, Lian Bijun, Wang Yan, Zhang Wenhui, Zhu Feng, Wang Tao, Yue Xiaodong, Jia Zepeng, Chen Huan, Li Husheng, Li Jing, Gao Xu
Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai, People's Republic of China.
Department of Urology, The 903th PLA Hospital, Hangzhou, People's Republic of China.
Int J Gen Med. 2021 May 3;14:1631-1640. doi: 10.2147/IJGM.S302105. eCollection 2021.
Through an observational study to present a new approach for obtaining high-quality samples for the targeted therapy of prostate cancer.
Parallel biopsy, which was defined as collecting the tissue from the same site by two biopsies, was performed on patients with elevated PSA. Each tissue was stained by ink to identify the pathological characteristics, including Gleason score and tumor tissue ratio. Kendall tau-b test and intraclass correlation coefficient test were used to compare the consistency between each paired sample. Then, based on the pathology of the biopsies, high-quality tissues would be selected for sequencing, and PyClone model was used to track the clonal evolution.
In total, 252 pairs of biopsies were collected. The consistency of Gleason score between each paired biopsy is 0.777 (<0.01), and the consistency of tumor tissue ratio is 0.853 (<0.01). With the application of parallel biopsy, on average five nonsynonymous mutations could be identified in patients with castration-resistant prostate cancer. Six out of eight had at least one biology-relevant alteration in patients, guiding further treatment. Meanwhile, clonal evolution was constructed to investigate the progress of tumor.
Parallel biopsy is a reliable approach to collect high-quality tissue and shows potential application in precision medicine.
通过一项观察性研究,提出一种获取高质量样本用于前列腺癌靶向治疗的新方法。
对前列腺特异性抗原(PSA)升高的患者进行平行活检,即通过两次活检从同一部位采集组织。每个组织用墨水染色以识别病理特征,包括 Gleason 评分和肿瘤组织比例。采用肯德尔 tau-b 检验和组内相关系数检验来比较每对样本之间的一致性。然后,根据活检的病理结果,选择高质量组织进行测序,并使用 PyClone 模型追踪克隆进化。
共收集了 252 对活检样本。每对活检样本之间 Gleason 评分的一致性为 0.777(<0.01),肿瘤组织比例的一致性为 0.853(<0.01)。通过应用平行活检,在去势抵抗性前列腺癌患者中平均可鉴定出五个非同义突变。八名患者中有六名至少有一个生物学相关改变,为进一步治疗提供了指导。同时构建克隆进化来研究肿瘤进展。
平行活检是一种可靠的获取高质量组织的方法,在精准医学中显示出潜在应用价值。